Oral isotretinoin as first-line systemic therapy in a case of extensive genital warts

Sivasankari, M; Adityan, M Subramania

doi:10.4103/ijstd.ijstd_121_20

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the mechanism is not fully understood, systemic therapy, especially parenteral administration, is thought to be effective in inducing systemic T-cell-mediated immune responses. Cytokines released from Th1 cells such as IL-2 and IFN-γ were mostly increased in response to injection [59,60].…”

Section: Systemic Immunotherapymentioning

confidence: 99%

The role of intralesional immunotherapy in Condyloma Acuminata

Lita Setyowatie,

Putri Mulia Bela Grania Hasibuan

2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Intralesional immunotherapy is one of the immunotherapy modalities that can be given to patients with condyloma acuminata (CA) with a high success rate both in inhibiting progression and preventing recurrence of genital warts. Intralesional immunotherapy regimens that are currently being studied are the use of vaccines and cytokines. Some of the antigens studied for use as therapy in genital warts include Candida albicans, measles, mumps and rubella (MMR), and Tuberculin/Purified Protein Derivate (PPD), Mycobacterium w, and Bacille Calmette-Guerin (BCG). Vaccines and cytokines work by inducing a delayed-type hypersensitivity response to warts tissue, both through cellular and humoral immune responses, mediated by CD8+ T lymphocytes, CD4+ T lymphocytes, B lymphocytes and regulatory T cells so that this can eliminate HPV virus infection in CA. This literature review aims to provide an understanding of the use of intralesional immunotherapy as an effective alternative therapy in CA.

show abstract

Section: Systemic Immunotherapymentioning

confidence: 99%